{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-22-047653","form_type":"8-K","ticker":null,"cik":"0001113148","company_name":"INFINITY PHARMACEUTICALS, INC.","filed_at":"2022-12-30T23:59:59+00:00","discovered_at":"2026-05-14T18:03:49.649132+00:00","generated_at":"2026-06-20T21:19:53.445107+00:00","sec_items":["3.01"],"event_type":"regulatory","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Infinity Pharma receives Nasdaq delisting notice for bid price below $1.00","bullets":["Nasdaq letter received Dec 28, 2022; common stock bid price under $1.00 for 30 consecutive days.","Company has 180 calendar days, until June 26, 2023, to regain compliance.","Compliance requires closing bid price of $1.00+ for 10 consecutive business days.","If not cured, may transfer to Nasdaq Capital Market for an additional 180-day period.","Management will monitor bid price and evaluate options to regain compliance."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-22-047653","json":"https://secwatch.observer/filing/0001140361-22-047653.json","markdown":"https://secwatch.observer/filing/0001140361-22-047653.md","text":"https://secwatch.observer/filing/0001140361-22-047653.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1113148/000114036122047653/0001140361-22-047653-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1113148/000114036122047653/brhc10046105_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-20T21:19:53.445107+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"65d0fef117574bd8235bcad26185b83fc88b0122","claim":"INFINITY PHARMACEUTICALS, INC. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1)).","evidence_excerpt":"December 28, 2022, Infinity Pharmaceuticals, Inc. (the “Company”) received a deficiency letter (the “Notice”) from the Listing Qualifications Department (the “Staff”) of the Nasdaq Stock Market, LLC (“Nasdaq”) notifying the Company that, for the last 30 consecutive business days, the bid price for the Company’s common stock (the “Common Stock”) had closed below $1.00 per share, which is the minimum bid price required to maintain continued listing on the Nasdaq Global Select Market under Nasdaq Listing Rule 5450(a)(1) (the “Minimum Bid Requirement”). The Notice has no immediate effect on the","evidence_source":"SEC 8-K Item 3.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1113148/000114036122047653/0001140361-22-047653-index.htm","confidence":0.9,"family_label":"Listing & Compliance Notices","details":[{"label":"Exchange","value":"nasdaq"},{"label":"Notice","value":"deficiency notice"},{"label":"Deficiency","value":"minimum bid price"},{"label":"Rules","value":"5450(a)(1)"}],"fact_type":"exchange_compliance_notice"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}